|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2007-5-25
|
|
pubmed:abstractText |
Oral treatment with prednisone has demonstrated efficacy in reducing restenosis after percutaneous coronary interventions (PCI). However, administration of steroids at high dose may raise concerns in terms of applicability and tolerability. Monitoring the occurrence of possible side-effects is therefore mandatory.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0896-4327
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
209-13
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17524113-Aged,
pubmed-meshheading:17524113-Angioplasty, Balloon, Coronary,
pubmed-meshheading:17524113-Anti-Infective Agents,
pubmed-meshheading:17524113-Coronary Restenosis,
pubmed-meshheading:17524113-Drug Toxicity,
pubmed-meshheading:17524113-Humans,
pubmed-meshheading:17524113-Male,
pubmed-meshheading:17524113-Middle Aged,
pubmed-meshheading:17524113-Neutropenia,
pubmed-meshheading:17524113-Prednisone,
pubmed-meshheading:17524113-Prospective Studies,
pubmed-meshheading:17524113-Pyridines,
pubmed-meshheading:17524113-Risk Factors
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Neutropenia in patients treated with thienopyridines and high-dose oral prednisone after percutaneous coronary interventions.
|
|
pubmed:affiliation |
Division of Cardiology of the University of Verona, Verona, Italy. flavio.ribichini@univr.it
|
|
pubmed:publicationType |
Journal Article
|
